Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05616728 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
A Phase 2 study of COVID-19, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
- 20
- Study locations
NCT05616728: Completed Phase 2 study of COVID-19, sponsored by Enanta Pharmaceuticals.
NCT05616728 is a Phase 2 study of COVID-19 that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 231 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05616728, a Phase 2 study of COVID-19, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EDP-235
Study Locations (20)
Florida
- MedBio Trials - Miami - Aventura
- Doral Medical Research - Doral
- Encore Medical Research - Hollywood - Hollywood
- Universal Medical and Research Center, LLC - Hollywood
- Advanced Research for Health Improvement, LLC - Immokalee
- LCC Medical Research - Miami - ClinEdge - PPDS - Miami
- USPA Advance Concept Medical Research Group. LLC - Miami
- Continental Clinical Research, LLC - Miami
- Dynamic Medical Research, LLC - Miami - Miami
- BioClinical Research Alliance - Miami
- D&H National Research Centers - Miami
- Florida International Medical Research - Miami
- C'A Medical Center Inc Research - Miami
- Reed Medical Research - Miami
- CDC Research Institute, LLC - Port Saint Lucie
California
- Torrance Clinical Research Institute - Lomita
- LA Universal Research Center, Inc. - Los Angeles
North Carolina
- Carolina Research Center - Shelby
Ohio
- Toledo Institute of Clinical Research - Toledo
Texas
- Trio Clinical Trials LLC - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2022-11-10 |
| Est. Completion | 2023-06-29 |
| Phase | Phase 2 |
What the finished NCT05616728 record still lists
NCT05616728 is an interventional study that assigns participants to a tested intervention. The registered 231 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05616728 names 20 study sites across 5 states, led by Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05616728 about?
NCT05616728 is a clinical study titled "A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19". Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
What is the current status of trial NCT05616728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2022-11-10. Estimated completion is 2023-06-29.
What conditions does trial NCT05616728 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05616728?
The interventions under investigation include: Placebo (DRUG), EDP-235 (DRUG).
Who is sponsoring clinical trial NCT05616728?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05616728 being conducted?
This trial has 20 study locations across California, Florida, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05616728's enrollment target sits among peer trials
231 154th of 298 higher than 145 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04077099 · 231 participants · Phase 1
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
- NCT05019495 · 231 participants · NA
Optimizing Tobacco Treatment Delivery for People Living With HIV
- NCT06023589 · 231 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- NCT06734351 · 231 participants · Phase 3
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI